Business
Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth Opportunities
Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth Opportunities\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n – Webcasted Q2-2025 conference call scheduled for\n \n August 26\n \n\n th\n \n at\n \n 5:00 PM EDT\n \n –\n \n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n Aug. 11, 2025\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, today announced preliminary unaudited revenues for the second quarter ended\n \n June 30, 2025\n \n , senior management changes, and the creation of a Perimeter Industry Advisory Board (\"IAB\").\n \n\n\n Preliminary Unaudited Second Quarter 2025 Revenues\n \n\n\n Unless otherwise indicated, all amounts in this press release are expressed in U.S. dollars.\n \n\n Perimeter anticipates total revenue for the second quarter of 2025 to be approximately\n \n $500,000\n \n , representing year-over-year growth of approximately 100%. Sequentially, the Company expects that greater than 35% procedure growth will result in over 50% recurring revenue growth in Q2-2025 compared to Q1-2025. This was primarily driven by stronger current Perimeter S-Series system utilization, with significantly more interoperative OTC imaging procedures performed by existing surgeon users, and at a higher price per procedure.\n \n\n For the six-month period ended\n \n June 30, 2025\n \n , total revenue is expected to be approximately\n \n $1.0 million\n \n , compared to\n \n $345,000\n \n in the 6-month period ended\n \n June 30, 2024\n \n and\n \n $846,000\n \n for the full year ended\n \n December 31, 2024\n \n .\n \n\n Gross margin is expected to be approximately 69% for the second quarter and 61% for the six-month period ended\n \n June 30, 2025\n \n , respectively.\n \n\n \"We are excited that the growing adoption, both in t...